Skip to content

The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery

The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (IMPALA ERAS)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07224711
Acronym
IMPALA ERAS
Enrollment
2290
Registered
2025-11-05
Start date
2026-10-31
Completion date
2028-10-31
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Consumption, Postoperative, Pain, Post Operative Analgesia

Brief summary

The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).

Interventions

DRUGLidocaine HCl 0.8% in D5W

1.5 mg /kg bolus of 0.8%lidocaine HCl in D5W via IV with induction, prior to infusion started. The IV bolus will be followed by continuous IV infusion of 2 mg/minute of 0.8% lidocaine HCl in D5W intraoperatively with weight-based gradated dosing postoperatively (1-2 mg/minute)

DRUGSodium Chloride 0.9%

Sodium chloride 0.9% via IV with induction, prior to infusion started. The IV bolus will be equivalent in volume to the lidocaine arm. The bolus will be followed by continuous IV infusion intraoperatively and then up to 48 hours. The continuous IV infusion will be equivalent in volume and rate to the lidocaine arm.

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age greater than or equal to 18 * American Society of Anesthesiologists (ASA) class II-IV * Presenting for major elective, non-cardiac surgery on the colorectal, emergency general surgery, urology, ventral hernia, surgical oncology, or spine services on a weekday * First surgery in the study period (if a patient has multiple surgeries, only the first will be included)

Exclusion criteria

* ASA class \>IV * Emergent procedures * Allergy or any contraindication to lidocaine infusion * Patient refusal * Unable to receive or refusal to receive a regional nerve block * Patients who receive an epidural due to standard of care * Direct transfer from operating room to ICU with endotracheal tube in place * Treating team determines patient ineligible prior to study drug administration * Same day surgery * Pregnancy (all female patient of child-bearing age will undergo a pregnancy test the day of surgery)

Design outcomes

Primary

MeasureTime frameDescription
Case Mix Index-Adjusted Resource Length of Stay (CARLOS)Hospital admission to discharge (usually 4-7 days)The difference of CARLOS between the placebo and experimental groups in days. The Case Mix Index-Adjusted Resource Length of Stay is a hospital quality metric that standardizes average length of stay (LOS) to account for the complexity and severity of a hospital's patient population, represented by its Case Mix Index (CMI). A higher CMI indicates a more resource-intensive patient group, while a lower CMI reflects a simpler, less costly case mix.
Total Inpatient opioid consumptionStart of study medication to 72 hoursTotal opioid consumption administered during the inpatient stay within the first 72 hours following initiation of the study medication. All opioid doses will be converted to oral morphine milligram equivalents (oMMEs) using standard conversion factors.

Secondary

MeasureTime frameDescription
Resource Length Of Stay (RLOS)Hospital admission to discharge (usually 4-7 days)Duration a patient spends in a healthcare facility as a measure of resource use
Case Mix IndexHospital admission to discharge (usually 4-7 days)The difference of Case Mix Index (CMI) between the placebo and experimental groups in days. The Case Mix Index is a hospital quality metric that reflects the average clinical complexity and resource intensity of the patient population. A higher CMI indicates a more resource-intensive patient group, while a lower CMI reflects a simpler, less costly case mix.
Total consumption of inpatient opioidsDay of surgery to hospital discharge (usually 4-7 days)Total consumption of inpatient opioids measured in oral morphine milligram equivalents (oMME)
Pain Visual Analog Score0 (first pain score in Post Anesthesia Care Unit (PACU) or Intensive Care Unit(ICU)), 4, 8, 12, 24, 48, 72 hours after PACU/ICU admission and at hospital dischargePain measured with an 11 point visual analog score (0 to 10) where 0 represents no pain and 10 represents the worst pain imaginable.
Incidence of surgical outcomesSurgery to 30 days after hospital dischargeIncidence of surgical outcomes such as bowel function, ileus, nausea, rapid response calls, surgical site infections, and Intensive Care Unit transfers
Incidence of treatment side effectsAnesthesia Induction to end of study treatment, less than or equal to 48 hoursIncidence of treatment side effects (double/blurry vision, tinnitus, sedation and events requiring early cessation of study treatment).
Incidence of meeting early discharge milestoneshospital discharge (usually 4-7 days after surgery)Incidence of hospital discharge earlier than expected based on anticipated discharge day indicated at initial hospital booking

Countries

United States

Contacts

CONTACTDanial Shams, MD
danial.shams@vumc.org615-936-3198
CONTACTMiklos Kertai, MD, MMHC, PhD
miklos.kertai@vumc.org
PRINCIPAL_INVESTIGATORDanial Shams, MD

Vanderbilt University Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026